Loading stock data…
$3.16+0.17 (+5.69%)
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products.
Indaptus Therapeutics, Inc. in the Healthcare sector is trading at $3.16 with a market capitalization of $369M. The stock is currently 47% below its 52-week high of $5.96, remaining 38.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.81M↑ | -$2.16M↑ | -$8.16M↓ | -$2.65M↑ | -$4.46M |
| Net Income | -$1.79M↑ | -$2.54M↑ | -$8.11M↓ | -$2.98M↑ | -$5.23M |
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity an...